stella
beta
Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma — Stella
Recruiting
Back to Multiple Myeloma trials
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations
(1 site)
China
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian
View full record on ClinicalTrials.gov